Comparative Efficacy of Belantamab Mafodotin in Combination With Bortezomib and Dexamethasone Versus Standards of Care in Patients With Third‐Line or Later Relapsed/Refractory Multiple Myeloma
American Journal of Hematology · 2026-09 · 101 (9) · 2435-2440
DOI: 10.1002/ajh.70408 ↗Kurz gefasst
Leserbrief in der Zeitschrift American Journal of Hematology, online erschienen am 12.06.2026. Verfasst von Joshua Richter und 7 weiteren Autor:innen. Beteiligte Einrichtung: Blavatnik Family Chelsea Medical Center, Mount Sinai, New York, New York, USA. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: GSK.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Blavatnik Family Chelsea Medical Center, Mount Sinai, New York, New York, USA.
- Division of Blood and Marrow Transplant, OhioHealth, Columbus, Ohio, USA.
- Texas Oncology-Tyler, Tyler, Texas, USA.
- Evidera, a Business Unit of PPD, Part of Thermo Fisher Scientific, Montreal, Quebec, Canada.
- Evidera, a Business Unit of PPD, Part of Thermo Fisher Scientific, London, UK.
- GSK, Upper Providence, Pennsylvania, USA.
ORCID-Profile: Joshua Richter
Förderung
- GSK
Zitieren
APA
Richter, J., Efebera, Y., Yimer, H., Shukla, P., Kapetanakis, V., Purser, M., Boytsov, N., & Ballew, N. (2026). Comparative Efficacy of Belantamab Mafodotin in Combination With Bortezomib and Dexamethasone Versus Standards of Care in Patients With Third‐Line or Later Relapsed/Refractory Multiple Myeloma. American Journal of Hematology, 101(9), 2435-2440. https://doi.org/10.1002/ajh.70408
Vancouver
Richter J, Efebera Y, Yimer H, Shukla P, Kapetanakis V, Purser M, et al. Comparative Efficacy of Belantamab Mafodotin in Combination With Bortezomib and Dexamethasone Versus Standards of Care in Patients With Third‐Line or Later Relapsed/Refractory Multiple Myeloma. American Journal of Hematology. 2026;101(9):2435-2440. doi:10.1002/ajh.70408
BibTeX
@article{Richter2026,
author = {Richter, Joshua and Efebera, Yvonne and Yimer, Habte and Shukla, Pragya and Kapetanakis, Venediktos and Purser, Molly and Boytsov, Natalie and Ballew, Nick},
title = {Comparative Efficacy of Belantamab Mafodotin in Combination With Bortezomib and Dexamethasone Versus Standards of Care in Patients With Third‐Line or Later Relapsed/Refractory Multiple Myeloma},
journal = {American Journal of Hematology},
year = {2026},
volume = {101},
number = {9},
pages = {2435--2440},
doi = {10.1002/ajh.70408}
}
EUVIMED